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Word count: 4937 
Abstract 
 
Background: A previous economic analysis of self-management, that is, self-monitoring 
with self-titration of antihypertensive mediation evaluated cost-effectiveness among 
patients with uncomplicated hypertension. This study considered cost-effectiveness of 
self-management in those with raised blood pressure plus diabetes, chronic kidney disease 
(CKD) and/or previous cardiovascular disease. 
 
Design and methods: A Markov model-based economic evaluation was undertaken to 
estimate the long-term cost-effectiveness of self-management of blood pressure in a 
cohort of 70-year old ‘high risk’ patients, compared with usual care. The model used the 
results of the TASMIN-SR trial. A cost-utility analysis was undertaken from a UK health 
and social care perspective, taking into account lifetime costs of treatment, cardiovascular 
events and quality adjusted life years (QALYs). A sub-group analysis ran the model 
separately for men and women. Deterministic sensitivity analyses examined the effect of 
different time horizons and reduced effectiveness of self-management. 
 
Results: Base-case results indicated that self-management was cost-effective compared 
with usual care, resulting in more QALYs (0.21) and cost savings (-£830) per patient. 
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There was a 99% chance of the intervention being cost-effective at a willingness to pay 
threshold of £20,000 per QALY gained. Similar results were found for separate cohorts 
of men and women. The results were robust to sensitivity analyses, provided that the 
blood pressure lowering effect of self-management was maintained for more than a year. 
 
Conclusion: Self-management of blood pressure in ‘high risk’ people with poorly 
controlled hypertension not only reduces blood pressure, compared with usual care, but 
also represents a cost-effective use of health care resources. 
 
Word count: 250 
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Background 
Hypertension is a leading risk factor for cardiovascular mortality and morbidity 
worldwide.1, 2 Despite evidence of cost saving from antihypertensive treatment,3 and 
improvements in blood pressure monitoring, management and treatment,3, 4 significant 
numbers of people remain inadequately controlled hence new models of care are 
required.5 Self-management of hypertension, where an individual self-monitors their own 
blood pressure (BP) and adjusts their own medication has been shown to lead to 
significantly lower BP in hypertension, including in those with higher cardiovascular 
risk.6, 7  
 
The only economic analysis of self-management in the control of hypertension to date 
demonstrated that tele-monitoring with self-titration in uncomplicated hypertension was 
highly cost-effective with incremental cost-effectiveness ratios (ICERs) below £5,000 
QALY gained for men and women, when modelled over patient lifetime.8 However 
subgroup analysis in the main trial suggested that the intervention might not be as 
effective in those with significant co-morbidities, although patient numbers for this sub-
group were small.7 Therefore, the TASMIN-SR trial was undertaken to determine the 
effect of self-monitoring with self-titration of antihypertensive medication on systolic BP 
among hypertensive patients with sub-optimal control and pre-existing cardiovascular 
disease, diabetes mellitus (DM) and/or CKD, compared with usual care. A model-based 
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probabilistic cost-utility analysis was undertaken as part of this study to assess the long-
term cost-effectiveness of the self-management intervention in a ‘high risk’ patient 
population, compared with usual care.  
 
Methods 
A Markov cohort model, built in TreeAge Pro (TreeAge Software Inc, Williamstown, 
MA, USA), was developed to estimate the long-term cost-effectiveness of self-
management of BP compared with usual care, in patients with hypertension and a history 
of stroke, coronary heart disease (CHD), DM or CKD. The analysis used the results of 
the TASMIN-SR trial on BP, extrapolating these to long-term risk of cardiovascular 
endpoints [see below]. Full details of the trial methods and results have been described in 
detail elsewhere.6, 9 The model was run over a lifetime (30 year) time horizon using a six-
month time cycle, with results presented from a UK National Health Service (NHS) and 
Personal Social Services (PSS) perspective. 
 
Study population 
The base case analysis considered a cohort of 70 year old patients (39% female) with sub-
optimal hypertension, BP ≥ 130/80 mmHg at baseline, combined with a history of stroke, 
CHD, DM or CKD.6 Patients had at least one of four main underlying conditions (DM, 
stroke, CHD and CKD), to be eligible with 15 possible combinations of high risk 
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conditions in total. Further details of the combined risk conditions are available in the 
supplemental online document, eTable 2. 
 
Interventions 
Patients randomised to usual care booked an appointment for a routine BP pressure check 
and medication review with the study general practitioner (GP). Thereafter, usual care 
consisted of the participants seeing their GP and or nurse for routine BP measurement 
and adjustment of medication at the discretion of the health professional. Patients 
randomised to self-management were trained to self-monitor BP and to self-titrate their 
antihypertensive medication following a predetermined plan, in two or three sessions, 
each lasting around an hour. Following training, patients adjusted their antihypertensive 
medication based on their monthly self-monitored BP readings.9  
 
Model structure 
A patient entered the model in the “high risk” health state and could move to another 
health state if they suffered one of three possible cardiovascular (CV) events (stroke, 
myocardial infarction (MI), unstable angina (UA)), or died from other causes (figure 1). 
After a CV event, individuals could survive from that event or die within the first 6 
months. Those that survived an event subsequently moved to a chronic health state for 
that condition until death, with no recurrences of CV events. For each chronic health state, 
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an ongoing health care cost was applied every time cycle and quality of life was 
permanently reduced. Movement between health states was defined by transition 
probabilities, which represented the risk of experiencing an event within each six-month 
time cycle.  
 
Model parameters 
Patient level data from the TASMIN-SR trial were used to reflect the CV disease history 
of patients entering the Markov model. The probabilities of suffering a stroke, MI or 
developing UA were obtained from published literature for hypertensive patients with 
each of the high risk conditions10-14 (Table 1). Where the model required probabilities that 
were not available in the literature (for given age group, gender or combination of high 
risk conditions), missing values were estimated through extrapolation (see supplemental 
online document). For patients presenting with two or more high risk conditions, the 
probability of an event was calculated as the sum of the two individual risk probabilities 
(supplemental online document, etables 1 and 2).  
 
Systolic BP reductions recorded in the trial at 6 months (11.4mmHg and 5.5mmHg for 
the intervention and control arms) and at 12 months (15.0mmHg and 5.8mmHg for the 
intervention and control arms) were extrapolated to age-related risk reductions for CHD 
(comprising both MI and UA) and stroke, using Law et al15 (Table 1). Relative risks for 
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CHD and stroke related to 6 and 12 month BP reductions are reported in Table 1. The 
model assumed that BP remained static for the first six month cycle of the model, then 
reduced as per the 6 month trial results for the second model cycle followed by the 12 
month trial reductions thereafter with the between groups differences assumed constant 
in the base case.  The probabilities of death from MI and stroke within a year of the event 
are reported in Table 1 and applied to the first year after an event (first two cycles in the 
model). Life tables were used to determine overall mortality, dependent on age and 
gender.16  
 
Resource use and costs 
Costs are reported in UK pounds at 2011/12 prices. Resource use related to ongoing BP 
monitoring in primary care, self-management and prescription of antihypertensive was 
obtained from the TASMIN-SR trial at 12 months follow-up. For self-management, 
equipment and training costs were annuitized at an annual rate of 3.5% and based on a 
lifetime of five years.17 Replacement costs for the equipment and training were included 
at five yearly intervals over the lifetime of the model (supplemental online document, 
eTable 3). Equipment used by individuals who died within any five year interval was 
assumed to be discarded. Unit costs were applied to resource use and mean patient costs 
per six months were calculated for both randomised groups, and applied to the initial high 
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risk health state. Costs for acute and chronic CV event states were obtained from 
published studies.14, 18-20 See Table 1.  
 
Utility values 
The primary outcome measure was QALYs. All utility scores used in the model are shown 
in Table 1. The utility values for the starting ‘high risk’ health state were obtained from 
the TASMIN-SR trial where the overall mean EQ-5D score for hypertensive patients at 
baseline was used to estimate utilities. This was adjusted for age group using weights 
calculated from Ara et al,21 which allowed the overall reduction in quality of life with 
increasing age to be incorporated in the model. Acute events were assumed to happen 
approximately three months into a six-month cycle and individuals stayed in that acute 
state for three months before moving into a chronic state. Therefore utilities for the acute 
state were applied mid-way through the six-month cycle and chronic health state utilities 
were applied at the start of the subsequent cycle (table 1). Health state utilities for CV 
events were applied multiplicatively to the age-related ‘high risk’ health state utility 
values.   
 
Analysis 
A cost-utility analysis was undertaken from a UK NHS and PSS perspective. For the base-
case analysis, fifteen separate cost-effectiveness analyses were run, one for each 
10 
 
combination of high risk conditions assessed in the model. The final cost-effectiveness 
results correspond to the trial population-weighted average of costs and quality adjusted 
life years (QALYs) and are reported in terms of the incremental cost per QALY gained.22 
Analyses were also separately run for men and women. Costs and outcomes were 
discounted at an annual rate of 3.5%.23 
 
Uncertainty in the model results was assessed using sensitivity analyses. Deterministic 
sensitivity analysis was undertaken around key parameters and assumptions. The time 
horizon for the model was varied from 30 years (lifetime) to between 1 year and 20 years, 
to determine whether the intervention was cost effective in the shorter term. The 
assumption regarding the long-term effectiveness of the intervention was tested by 
assessing the impact of limiting the additional effect on BP lowering to years of self-
management 1, 2, 5 and 10. Additional sensitivity analyses altered long term CV event 
costs by 30% (up and down). Finally, all analyses were re-run using the un-adjusted trial 
data which showed marginally smaller reductions in BP (11.4 mmHg and 5.8 mmHg for 
the intervention and control arms at 6 months and 14.9 mmHg and 6.0 mmHg respectively 
at 12 months). Where possible, data were entered into the model as distributions in order 
that a probabilistic sensitivity analysis (PSA) could be undertaken to incorporate 
parameter uncertainty. Gamma distributions were fitted to all costs obtained from the 
TASMIN-SR trial and beta distributions were applied to the utility values. The parameters 
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used for these distributions are shown in Table 1. The PSA was run with 10,000 2nd order 
Monte Carlo simulations and cost-effectiveness planes (CEPs) and cost-effectiveness 
acceptability curves (CEACs) constructed, to estimate the probability of self-management 
being cost-effective at different willingness-to-pay thresholds.17 
 
Results 
In the base-case analysis, self-management of BP was dominant compared to usual care, 
being cheaper and more effective (Table 2). Self-management was associated with mean 
cost savings of £830 per patient for the total population (self-management £7,357 vs. 
usual care £8,187) and a gain of 0.21 QALYs (6.25 vs. 6.03, respectively). This 
dominance was demonstrated for both men and women (Table 2). In the CEP (Figure 2), 
all results are in the north-east and south-east quadrants indicating that self-management 
is always more effective but with greater uncertainty around the difference in costs. The 
CEAC shows that the probability of self-management of BP being cost-effective 
compared with usual care was at least 99% if decision makers were willing to pay £20,000 
per QALY gained. At a lower threshold of £10,000 per QALY, the probability of the 
intervention being cost-effective compared with usual care was still high at 97% (Figure 
2). 
A sensitivity analysis of time horizon demonstrated that self-management is dominant if 
the horizon is two years or more (Table 3).  Similarly, if the impact of self-management 
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on BP is time limited, the cost-effectiveness is reduced – but the intervention is still cost-
effective provided that the effect is sustained for one year (first two cycles) (Table 4). 
Other sensitivity analyses (costs and reduced impact on BP) did not change the overall 
results (see supplemental online document, etables 4-6).  
  
Discussion 
This is the first study to present results of the cost-effectiveness of self-management of 
BP compared with usual care in a high risk population with sub-optimally managed 
hypertension and significant CV comorbidity. The base-case analysis suggests that self-
management of BP is cost-effective and is likely to be dominant (i.e., it is less costly and 
produces more QALYs) compared to usual care.  
 
The main driver of this result is the estimated decline in the risk of CV events associated 
with the observed additional BP lowering achieved with self-management, and this 
explanation also holds for the greater benefit seen for men. This result was robust to 
sensitivity analysis unless the time horizon was reduced below two years or the observed 
BP lowering effect of self-management did not continue beyond a year. 
 
Relationship with other literature 
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Previous economic studies have evaluated the cost-effectiveness of self-monitoring rather 
than self-management (self-monitoring plus self-titration of antihypertensive) and only 
one previous economic analysis of self-management has been undertaken (TASMINH2)8, 
which found self-management to be cost-effective (£1,624 and £4,923 per QALY gained 
for men and women respectively).8 In this analysis, we found self-management to be even 
more cost-effective, reflecting the higher number of CV events predicted to have been 
prevented in the higher risk population, and the slightly greater reductions in BP that were 
observed in the TASMIN-SR trial. 
 
Strengths and limitations  
This study used cost and outcome data of trial participants6 who may differ from similar 
patients not taking part in the trial for instance being more adherent and healthier.24 The 
strongly positive results however suggest that such an intervention would be cost-
effective even in a less compliant population.  The costs of long-term and acute care were 
taken from estimates in the literature and a number of assumptions were made about the 
annual probabilities of CV events by risk conditions based on best published information. 
A key assumption was that of the prolonged effectiveness of the intervention. In both 
TASMINH2 and TASMIN-SR, the difference in BP reduction between trial arms 
continued to diverge between 6 and 12 months suggesting that the effect may be 
maintained over time. Indeed, an 18 month post trial follow up of the HSM self-
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management trial found that BP continued to diverge over time suggesting our 
assumption of maintenance of effect may even be conservative.25 The sensitivity analyses 
showed that even if BP differences lasted only one further year and then returned to the 
effectiveness of usual care, self-management is still likely to be cost effective. For 
simplicity, the model did not include subsequent CV events. Given that the main driver 
of costs was events and the main driver of events was BP, it would be expected that a 
model including secondary and subsequent events would show self-management to be 
even more cost-effective than usual care. The model considers patients with co-
morbidities and additional risk factors (e.g. age, gender). Arguably, a more complex 
model such as individual patient level simulation could be more appropriate in this 
situation, as this type of model can incorporate patient history more efficiently, 
overcoming the limitations of Markov models.26 Finally, an assumption has been made 
regarding the differential effect of BP lowering between the intervention and control 
groups. Systematic reviews suggests that lowering BP below 140/90 mmHg is as effective 
as lowering BP to 140/90 mm Hg,15 but it is fair to say that the evidence of benefit is 
stronger in stroke and DM than in CHD or CKD.10, 27-29 
 
Clinical implications 
These results suggest that the benefits of BP reduction seen in the trial can be achieved in 
a highly cost-effective manner. The up-front costs of implementation of self-management 
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of hypertension in high risk groups are relatively modest (£14.6 equipment and £20.0 
training) and are soon repaid by future maintenance of quality of life and reductions in 
costs from reduced CV events. The very high likelihood of cost-effectiveness from both 
this and the previous analyses suggests that self-management is a strong candidate for 
implementation.  
 
Conclusions 
The results of this model-based economic evaluation suggest that self-management of 
hypertension in high risk patients is a cost-effective strategy in the short and long term, 
resulting in QALY gains and cost-savings. Self-management of BP in high risk patients 
represents an important new addition to the management of hypertension in primary care. 
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Table 1 Model parameters  
Parameter Value  Source 
 
Reduction in systolic BP at 12 months (mmHg)  TASMIN-SR trial6 
Self-management 15.0   
Usual care 5.8   
Reduction in systolic BP at 6 months (mmHg)  TASMIN-SR trial6 
Self-management 11.4   
Usual care 5.5   
Annual transition probabilities    
CVD events for patients with DM  NICE Diabetes guidelines, Appendix D112 
Stroke    
60-69 years old 0.0196   
70-79 years old 0.0262   
80-89 years old 0.0298   
MI (MI) 
60-69 years old 0.0089   
70-79 years old 0.0100   
80-89 years old 0.0111   
UA (UA) 
60-69 years old 0.0041   
70-79 years old 0.0047   
80-89 years old 0.0052   
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CVD events for patients with CKD   Kerr et al (2012)11 
Stroke    
60-69 years old 0.0072   
70-79 years old 0.0147   
80-89 years old 0.0189   
MI 
60-69 years old 0.0051   
70-79 years old 0.0113   
80-89 years old 0.0171   
UA 
60-69 years old 0.0024   
70-79 years old 0.0054   
80-89 years old 0.0081   
CVD events for patients with a previous stroke   
PROGRESS (1999) & NICE, Lipid  
modification guidelines10, 14 
Stroke    
60-69 years old 0.0348   
70-79 years old 0.0589   
80-89 years old 0.0713   
MI 
60-69 years old 0.0139   
70-79 years old 0.0232   
80-89 years old 0.0232   
UA 
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60-69 years old 0.0139   
70-79 years old 0.0232   
80-89 years old 0.0232   
CVD events for patients with CHD  
NICE, Lipid modification guidelines14 and 
NICE Hypertension guidelines4 
Stroke    
60-69 years old 0.0359   
70-79 years old 0.0588   
80-89 years old 0.0713   
MI 
60-69 years old 0.0666   
70-79 years old 0.1112   
80-89 years old 0.1112   
UA 
60-69 years old 0.0528   
70-79 years old 0.0881   
80-89 years old 0.0881   
Age-related relative risks at 12 months (95% CI)  TASMIN-SR trial & Law et al (2009)6, 15 
MI and UA – self-management     
60-69 years old 0.63 (0.60, 0.66)   
70-79 years old 0.68 (0.64, 0.71)   
80-89 years old 0.74 (0.70, 0.78)   
Stroke – self-management  
60-69 years old 0.53 (0.49, 0.57)   
70-79 years old 0.59 (0.55, 0.64)   
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80-89 years old 0.74 (0.69, 0.79)   
MI and UA - usual care  
60-69 years old 0.83 (0.81,0.84)   
70-79 years old 0.85 (0.84,0.87)   
80-89 years old 0.89 (0.87,0.90)   
Stroke - usual care  
60-69 years old 0.77 (0.75, 0.79)   
70-79 years old 0.81 (0.79, 0.83)   
80-89 years old 0.89 (0.86, 0.91)   
Age-related relative risks at 6 months (95% CI)  TASMIN-SR trial & Law et al (2009) 6, 15 
MI and UA – self-management     
60-69 years old 0.71 (0.68, 0.73)   
70-79 years old 0.75 (0.72, 0.77)   
80-89 years old 0.80 (0.76, 0.83)   
Stroke – self-management  
60-69 years old 0.62 (0.59, 0.66)   
70-79 years old 0.68 (0.64, 0.71)   
80-89 years old 0.80 (0.76, 0.84)   
MI and UA - usual care  
60-69 years old 0.83 (0.82,0.85)   
70-79 years old 0.86 (0.85,0.87)   
80-89 years old 0.89 (0.87,0.91)   
Stroke - usual care  
60-69 years old 0.77 (0.75, 0.80)   
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70-79 years old 0.81 (0.80, 0.84)   
80-89 years old 0.89 (0.87, 0.91)   
Probability of death for those who have suffered an 
event   
Fatal stroke 0.23  Bamford et al (1990)30 
Fatal MI   
ONS, Deaths registry (2011)  &   
Kerr et al (2012) 11, 16 
65-74 years old 0.23   
75-84 years old 0.39   
85 and over 0.52   
Costs (UK £)    
Cost for the initial state a  
TASMIN-SR trial, Curtis L (2012) &  
BNF 20126, 31, 32 
Self-management b 183   
Usual care  125   
Costs of acute disease one-off cost    
Stroke 11,020  Youman et al (2003)20 
MI 5,487  Robinson et al (2004)19  
UA 3,292  Assumed 60% of MI 
Costs for long-term (chronic) disease per year  
Stroke 2,721  Youman et al (2003)20 
MI 572  NICE, Lipid Modification Guidelines 14 
UA 572  NICE, Lipid Modification Guidelines 14 
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Utilities    
Utilities for initial health state    
Self-management and usual care  TASMIN-SR Trial6 
65-74 years old 0.81   
75-84 years old 0.74   
85 and over 0.71   
Utilities for acute events  NICE, Lipid Modification Guidelines 14 
UA  0.77   
MI 0.76   
Stroke 0.63   
Utilities for long term (chronic) disease  NICE, Lipid Modification Guidelines 14 
UA  0.88   
MI  0.88   
Stroke 0.63   
Dead 0.00  by definition 
    
 
a
 Included annual costs of drugs per patient, average GP and PN cost of 
consultation(s) and the costs of the intervention. The cost difference between self-
monitoring and usual care was driven by the cost of the intervention 
b
 For greater detail see supplemental online document 
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Table 2 Results of cost-effectiveness analysis  
 
Costs QALYs 
Incremental 
cost 
Incremental 
QALYs ICER  
Total population      
Usual care 8,187 6.0326     
Self-management 7,357 6.2466  -830 0.2139 Dominant  
 
Women      
Usual care         
7,338  
         
6.2467        
Self-management         
6,579  
         
6.4456  -759 0.1988  Dominant  
 
Men      
Usual care         
8,654  
         
5.9035        
Self-management         
7,791  
         
6.1257  -864 0.2221  Dominant  
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Figure 2 Base-case results 
Incremental CEP: self-management against usual care 
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Table 3 Sensitivity analyses: cost-effectiveness by time horizon 
 Costs QALYs 
Incremental 
cost 
Incrementa
l QALYs ICER 
20-year      
Usual care 
        
7,709  
           
5.8830        
Self-management 
        
6,919  
           
6.0975  -789 0.2145 
 
Dominan
t  
 
10-year       
Usual care 
        
5,242  
           
4.7756        
Self-management 
        
4,675  
           
4.9252  -567 0.1496 
 
Dominan
t  
 
5-year       
Usual care 
        
2,882  
           
3.1178        
Self-management 
        
2,554  
           
3.1742  -328 0.0564 
 
Dominan
t  
 
3-year       
Usual care 
        
1,690  
           
2.0859        
Self-management 
        
1,535  
           
2.1044  -155 0.0186 
 
Dominan
t  
 
2-year       
Usual care 
        
1,116  
           
1.4651        
Self-management 
        
1,056  
           
1.4718  -59 0.0067 
 
Dominan
t  
1-year      
26 
 
Usual care 
           
603  
           
0.7729        
Self-management 
           
625  
           
0.7736  22 0.0006 
                 
34,791  
 
Table 4 Sensitivity analyses: cost-effectiveness by reducing the additional effect of self-
management to BP lowering at four different time points  
Time horizon  Costs QALYs 
Incrementa
l cost 
Incrementa
l QALYs 
ICER 
 
10 years  
Usual care 
        
8,187  
           
6.0326        
Self-management 
        
7,530  
           
6.2242  -657 0.1916  Dominant  
 
5 years  
Usual care 
        
8,187  
           
6.0326        
Self-management 
        
7,876  
           
6.1623  -311 0.1297  Dominant  
2 years   
Usual care 
        
8,187  
           
6.0326        
Self-management 
        
8,259  
           
6.0757  
                        
71  
                      
0.0430  
                   
1,660  
1 year  
Usual care 
        
8,187  
           
6.0326        
Self-management 
        
8,382  
           
6.0454  195 0.0127 
                 
15,341  
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